Research Topics
Genomes and GenesSpecies | N J TalleySummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Guidelines for the management of dyspepsiaNicholas J Talley
Division of Gastroenterology and Hepatology, Mayo Clinic, Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Gastroenterol 100:2324-37. 2005..pylori eradication fails. There are very limited data to support the use of low-dose tricyclic antidepressants or psychological treatments in functional dyspepsia...
Associations between respiratory symptoms, lung function and gastro-oesophageal reflux symptoms in a population-based birth cohortRobert J Hancox
Dunedin Multidisciplinary Health and Development Research Unit, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
Respir Res 7:142. 2006..The role of obesity in mediating this association is also unclear. We explored the associations between respiratory symptoms, lung function, and gastro-oesophageal reflux symptoms in a birth cohort of approximately 1000 individuals...
Shortening a survey and using alternative forms of prenotification: impact on response rate and qualityTimothy J Beebe
Division of Health Care Policy and Research, Mayo Clinic, 200 First Street Southwest, Rochester Minnesota 55905, USA
BMC Med Res Methodol 10:50. 2010..postcard) on measures of survey quality, including response rates, response times (days to return the survey), and item nonresponse...- Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studiesChristopher J Hawkey
Institute of Clinical Research, Trials Unit, Wolfson Digestive Diseases Centre, University Hospital, Derby Road, Nottingham, NG7 2UH, UK
Arthritis Res Ther 9:R17. 2007..The frequency of adverse events was similar in the three groups. Esomeprazole maintains relief of NSAID-associated upper GI symptoms in patients taking continuous NSAIDs, including selective COX-2 inhibitors... - Patient reported outcomes in gastroesophageal reflux disease: an overview of available measuresNicholas J Talley
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
Qual Life Res 14:21-33. 2005..The most frequently used instruments in GERD are reviewed here, in terms of their psychometric properties... 
A gap in our understanding: chronic constipation and its comorbid conditionsNicholas J Talley
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA
Clin Gastroenterol Hepatol 7:9-19. 2009....- Functional gastrointestinal disorders as a public health problemN J Talley
Department of Internal Medicine, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
Neurogastroenterol Motil 20:121-9. 2008.... - DyspepsiaNicholas J Talley
Motility Interest Group, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
Gastroenterology 125:1219-26. 2003 - Evaluation of drug treatment in irritable bowel syndromeNicholas J Talley
Mayo Clinic, Charlton 8 138, 200 First Street S W, Rochester, MN 55905, USA
Br J Clin Pharmacol 56:362-9. 2003..New visceral analgesic and motility modifying agents, as well as anti-inflammatory agents are in trials, and hopefully additional efficacious therapeutic options for patients with IBS will soon emerge... - Effects of desipramine and escitalopram on postprandial symptoms induced by the nutrient drink test in healthy volunteers: a randomized, double-blind, placebo-controlled studyNicholas J Talley
Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Digestion 72:97-103. 2005..We hypothesized that desipramine and escitalopram would enhance the maximum tolerated volume of nutrient ingested and decrease postprandial symptoms... - Helicobacter pylori: testing and treatmentNicholas J Talley
Department of Internal Medicine, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Expert Rev Gastroenterol Hepatol 1:71-9. 2007..Quadruple therapy is recommended if standard triple therapy fails. Salvage therapies with levofloxacin, rifabutin or furazolidone have been identified. Novel approaches to treatment include sequential therapy and use of adjuvants... - Functional nausea and vomitingNicholas J Talley
Mayo Clinic, Rochester, United States
Aust Fam Physician 36:694-7. 2007..However, there is little evidence that such a condition exists. Rather, these patients usually have a functional gastrointestinal disorder (functional nausea and vomiting)... - Functional dyspepsia, delayed gastric emptying, and impaired quality of lifeN J Talley
Mayo Clinic Clinical Enteric Neuroscience, Translational and Epidemiological Research Program CENTER and Mayo Clinic College of Medicine, 200 First Street SW, Plummer 6 56, Rochester, MN 55905, USA
Gut 55:933-9. 2006..We aimed to evaluate the relationship between functional dyspepsia symptoms, gastric emptying, and HRQOL... - Is it time to screen and treat H pylori to prevent gastric cancer?Nicholas J Talley
Department of Internal Medicine, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
Lancet 372:350-2. 2008 - Gut eosinophilia in food allergy and systemic and autoimmune diseasesNicholas J Talley
Division of Gastroenterology and Hepatology, Mayo Clinic Campus, Mayo Clinic, Jacksonville, FL 32224, USA
Gastroenterol Clin North Am 37:307-32, v. 2008..Parasitic, bacterial, and viral pathogens as well as certain systemic diseases such as vasculitis can cause gut eosinophilia. These heterogeneous conditions are reviewed in this article... - Commentary: Controversies in NICE guidance on irritable bowel syndromeNicholas J Talley
Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32082, USA
BMJ 336:558-9. 2008 - Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsiaN J Talley
Mayo Clinic Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
Aliment Pharmacol Ther 27:1122-31. 2008..However, its effect on satiation in functional dyspepsia is unclear, and any symptom benefit has not been explored... - Management issues in dyspepsia: current consensus and controversiesN J Talley
Division of Gastroenterology and Internal Medicine, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Scand J Gastroenterol 39:913-8. 2004 - Practical examples: trials and conclusions -- an interactive segmentN J Talley
Mayo Clinic of Medicine and Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
Aliment Pharmacol Ther 20:9-13; discussion 38-9. 2004..More generally, a lack of pre-defined primary end-points, clinically relevant and measured appropriately, is a common feature of reflux trial methodology... - What the physician needs to know for correct management of gastro-oesophageal reflux disease and dyspepsiaN J Talley
Center for Enteric Neurosciences and Translational Epidemiological Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Aliment Pharmacol Ther 20:23-30. 2004..However, a PPI trial may offer a similar outcome and may be preferable in low H. pylori prevalence areas; head-to-head management trials in primary care are lacking... - Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trialsN J Talley
Mayo Clinic College of Medicine, Department of Internal Medicine, 4500 San Pablo Road, Jacksonville, FL 32082, USA
Gut 57:740-6. 2008..Itopride, a prokinetic approved in several countries, showed promising efficacy in FD in a phase IIb trial. The aim of this study was to test the efficacy and safety of this drug in FD... - Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohortN J Talley
Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Neurogastroenterol Motil 16:413-9. 2004..01). Heartburn and diarrhoea were associated with increased BMI, while early satiety was associated with a lower BMI in this population... - The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazoleD Armstrong
McMaster University Medical Centre, Ontario, Canada
Aliment Pharmacol Ther 20:413-21. 2004..Standard-dose proton pump inhibitors can provide symptom relief in endoscopy-negative reflux disease but the effect of greater acid suppression has not been studied... - Eosinophilic and autoimmune gastrointestinal disease: new insights and new entities. PrefaceNicholas J Talley
Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
Gastroenterol Clin North Am 37:xi-xii. 2008 - Functional Dyspepsia: A New Rome III ParadigmSmita L S Halder
Nicholas J Talley, MD, PhD Department of Internal Medicine, Mayo Clinic Jacksonville, 4500 San Pablo Road, Davis 6 72 E, Jacksonville, FL 32224, USA
Curr Treat Options Gastroenterol 10:259-72. 2007..Emerging treatments include gastric fundus relaxors and visceral analgesics, although their application in FD is still in the preliminary stages... - Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?N J Talley
Mayo Clinic College of Medicine, Rochester, MN, USA
Aliment Pharmacol Ther 26:673-82. 2007..Early identification of true responders to acid suppression in functional dyspepsia patients with symptoms of epigastric pain or burning may enable clinicians to optimally tailor treatment... - Current treatments in functional dyspepsiaMeredythe A McNally
Nicholas J Talley, MD, PhD Mayo Clinic College of Medicine, Division of Gastroenterology, Dyspepsia Center, 200 First Street SW, PL 6 56, Rochester, MN 55905, USA
Curr Treat Options Gastroenterol 10:157-68. 2007..Antidepressant therapy may have a place in management of difficult cases, but adequate randomized controlled trials are unavailable... - How to manage the difficult-to-treat dyspeptic patientNicholas J Talley
Mayo Clinic, 200 First Street SW, Plummer 6 56, Rochester, MN 55905, USA
Nat Clin Pract Gastroenterol Hepatol 4:35-42. 2007..Antidepressants (especially low-dose tricyclic agents) and psychological therapies can be useful. Creation of a logical management plan that includes patient education and support remains key... - Review article: gastro-oesophageal reflux disease -- how wide is its span?N J Talley
Mayo Clinic College of Medicine and Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
Aliment Pharmacol Ther 20:27-37; discussion 38-9. 2004..Gastro-oesophageal reflux disease has also been implicated in an increasing array of other conditions, but arguably in these settings it is often over-diagnosed... - Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trialNicholas J Talley
Department of Medicine, Nepean Hospital, University of Sydney, Sydney, NSW, Australia
Dig Dis Sci 53:108-15. 2008..No trials have directly compared a tricyclic with a selective serotonin reuptake inhibitor. Our aim was to determine whether imipramine and citalopram are efficacious in IBS... - Genes and environment in irritable bowel syndrome: one step forwardN J Talley
Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, 200 First Street SW, PL-6-56, Rochester, MN 55905, USA
Gut 55:1694-6. 2006 - Irritable bowel syndromeN J Talley
Mayo Clinic College of Medicine, Dyspepsia Center, Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Rochester, Minnesota 55905, USA
Intern Med J 36:724-8. 2006..Management remains largely based on symptomatic rather than on disease-modifying therapy, but this is likely to change in the near future. Here, recent advances in the pathophysiology and management of IBS are considered... - Whither dyspepsia? A historical perspective of functional dyspepsia, and concepts of pathogenesis and therapy in 2009Nicholas J Talley
Mayo Clinic College of Medicine, Jacksonville, Florida, USA
J Gastroenterol Hepatol 24:S20-8. 2009..Better approaches for functional dyspepsia are likely to follow an improved understanding of the underlying pathophysiological abnormalities... - Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteersN J Talley
Translational and Epidemiological Research Program, Mayo Clinic Division of Gastroenterology and Hepatology, and Clinical Enteric Neuroscience, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Aliment Pharmacol Ther 24:859-67. 2006..The effects of tegaserod on gastric accommodation and postprandial satiety remain unclear... - Predictors of the placebo response in functional dyspepsiaN J Talley
Clinical Enteric Neuroscience, Translational and Epidemiological Research Program CENTER, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Aliment Pharmacol Ther 23:923-36. 2006..Trials in functional dyspepsia report placebo response rates of 30% to 40%... - Predictors of treatment response in patients with non-erosive reflux diseaseN J Talley
Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Aliment Pharmacol Ther 24:371-6. 2006..Up to 40% of patients with non-erosive reflux disease (NERD) fail to respond to proton pump inhibitor therapy... - Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adultsP Bytzer
Department of Medicine, University of Sydney, Nepean Hospital, Clinical Sciences Building, PO Box 63, Penrith, New South Wales 2751, Australia
Arch Intern Med 161:1989-96. 2001..CONCLUSIONS: Diabetes mellitus is associated with an increased prevalence of upper and lower gastrointestinal symptoms. This effect may be linked to poor glycemic control but not to duration of diabetes or type of treatment... - Risk factors for chronic diarrhoea in the community in the absence of irritable bowel syndromeJ Y Chang
Enteric Neuroscience Program, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Neurogastroenterol Motil 21:1060-e87. 2009..Chronic diarrhoea in the absence of IBS is common; self-reported food sensitivity, male gender and a lower level of education are risk factors... - Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of lifeN J Talley
Department of Medicine, University of Sydney, Nepean Hospital, Kingswood, New South Wales, Australia
Am J Gastroenterol 96:71-6. 2001..0001) associated with poorer quality of life in diabetes, independent of age, gender, smoking, alcohol use, and type of diabetes. CONCLUSIONS: GI symptoms impact negatively on health-related quality of life in diabetes mellitus... - A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteersR S Choung
Translational and Epidemiological Research Program C E N T E R, Mayo Clinic Division of Gastroenterology and Hepatology, Rochester, MN 55905, USA
Neurogastroenterol Motil 19:180-7. 2007..In healthy subjects, itopride reduced total PP gastric volume without accelerating gastric emptying or significantly altering gastric motor and sensory function in healthy individuals... - Relationship between upper gastrointestinal symptoms and changes in body weight in a population-based cohortF Cremonini
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Neurogastroenterol Motil 18:987-94. 2006..91, 16.2). No association was found between weight loss >10 lb and the studied symptom complexes. Moderate body weight increases and decreases are generally not associated with upper GI symptom changes over time in the general population... - Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms: a population based study in 15 000 Australian adultsP Bytzer
Department of Medicine, University of Sydney, Nepean Hospital, Penrith, Australia
Gut 49:66-72. 2001..Low socioeconomic class should be considered a risk factor for both upper and lower gastrointestinal symptoms... - Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsiaN J Talley
Department of Medicine, University of Sydney, Nepean Hospital, Penrith, NSW, Australia
N Engl J Med 341:1106-11. 1999..The relation between Helicobacter pylori infection and nonulcer dyspepsia is uncertain. We tested the hypothesis that curing the infection will relieve symptoms of dyspepsia... - Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study GroupN J Talley
Department of Medicine, University of Sydney, Nepean Hospital, Penrith, New South Wales 2751, Australia
BMJ 318:833-7. 1999..To determine whether eradication of Helicobacter pylori relieves the symptoms of functional dyspepsia... - Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 monthsN J Talley
Department of Medicine, University of Sydney, Nepean Hospital, Penrith, NSW, Australia
Aliment Pharmacol Ther 15:347-54. 2001..Most patients with gastro-oesophageal reflux disease (GERD), regardless of endoscopic status, suffer symptomatic relapse within 6 months of stopping acid suppressant therapy... - Combined analysis of the ORCHID and OCAY studies: does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms?S J O Veldhuyzen van Zanten
Division of Gastroenterology, Dalhousie University, Queen Elizabeth II Health Sciences Centre, Victoria General Site, Room 928 Centennial Building, 5790 University Avenue, Halifax, Nova Scotia, Canada B3H 2YG, Canada
Gut 50:iv26-30; discussion iv31-2. 2002..Recently, two very similar studies, the ORCHID and OCAY studies, have been completed and the combined results of these two multicentre, multinational, randomised, double blind, controlled clinical trials are reviewed... - Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole--results from the STARS II studyS Veldhuyzen van Zanten
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Aliment Pharmacol Ther 34:714-23. 2011..Patients with dyspepsia often experience troublesome symptoms... - Risk factors for chronic constipation and a possible role of analgesicsJ Y Chang
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Neurogastroenterol Motil 19:905-11. 2007..Chronic constipation is associated with use of acetaminophen, aspirin and non-steroidal anti-inflammatory drugs. The explanation of these associations requires further investigation... - Associations among binge eating behavior patterns and gastrointestinal symptoms: a population-based studyF Cremonini
Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Int J Obes (Lond) 33:342-53. 2009..Patients with bulimia have increased gastric capacity. The objective of the study was to examine if the severity of binge eating episodes would be associated with upper and lower GI symptoms... - The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trialR S Choung
Mayo Clinic Division of Gastroenterology and Hepatology, and Clinical Enteric Neuroscience, Translational and Epidemiological Research Program CENTER, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA
Neurogastroenterol Motil 20:220-7. 2008..28). Tricyclic and tetracyclic antidepressant agents do not appear to have significant effects on gastric motor or satiation postnutrient challenge in healthy individuals at the doses tested... - Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate cultureR S Choung
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
Aliment Pharmacol Ther 33:1059-67. 2011..There has been increasing interest in small intestinal bacterial overgrowth (SIBO) after reports of a link with irritable bowel syndrome (IBS), yet our understanding of this entity is limited... - Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsiaN Vakil
Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Aliment Pharmacol Ther 24:55-63. 2006..Aim To determine the incidence of symptoms of reflux disease and of erosive oesophagitis, and the relationship to changes in histological gastritis, in patients with non-ulcer dyspepsia over 12 months... - Predictors of gastroduodenal erosions in patients taking low-dose aspirinJ Hart
Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia
Aliment Pharmacol Ther 31:143-9. 2010..Gastroduodenal ulcers are common in patients taking low-dose aspirin. However, the factors predisposing to mucosal erosions, the precursor lesions, are not well known... - A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: a randomized, double-blind, placebo-controlled pharmacodynamic studyR S Choung
Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Jacksonville, FL, USA
Aliment Pharmacol Ther 27:404-11. 2008..However, its effect on gastro-oesophageal reflux or lower oesophageal sphincter pressure in humans remains unknown... - Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitusH H Xia
Department of Medicine, University of Sydney, Nepean Hospital, Penrith, NSW, Australia
Am J Gastroenterol 96:1039-46. 2001..Smoking was a risk factor for bloating and early satiety. CONCLUSIONS: H. pylori infection appears not to be associated with diabetes mellitus or upper GI symptoms in diabetes mellitus... - Sleep disturbances are linked to both upper and lower gastrointestinal symptoms in the general populationF Cremonini
Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Rochester, MN, USA
Neurogastroenterol Motil 21:128-35. 2009..Overall, sleep scores and GI symptom scores were both significant independent predictors of impaired QOL. In the community, reporting poor sleep is associated with upper and lower GI symptoms, but this is independent of BMI... - Novel associations with dyspepsia: a community-based study of familial aggregation, sleep dysfunction and somatizationN Gathaiya
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN and Mayo Clinic Florida, Jacksonville, FL 32224, USA
Neurogastroenterol Motil 21:922-e69. 2009..Familial aggregation raises the possibility of a genetic component, although environmental factors also need to be considered. Sleep dysfunction and somatization suggest a primary psychological component... - Dyspepsia consulters and patterns of management: a population-based studyS K Ahlawat
Clinical Enteric Neurosciences and Epidemiological Research, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
Aliment Pharmacol Ther 22:251-9. 2005..Although dyspepsia is common, management patterns in the United States are unknown... - Rectal bleeding: epidemiology, associated risk factors, and health care seeking behaviour: a population-based studyG D Eslick
School of Public Health, The University of Sydney, Sydney, New South Wales, Australia
Colorectal Dis 11:921-6. 2009..Moreover, there is little information as to whether individuals seek health care for this problem. This study aimed to determine the prevalence of rectal bleeding and levels of healthcare seeking amongst an Australian population... - Cumulative incidence of chronic constipation: a population-based study 1988-2003R S Choung
Dyspepsia Center and Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Aliment Pharmacol Ther 26:1521-8. 2007..To estimate the cumulative incidence of chronic constipation and evaluate potential risk factors... - Health care seeking for abdominal bloating and visible distentionX Jiang
Department of Internal Medicine and Division of Gastroenterology and Hepatology, Mayo Clinic, College of Medicine, Rochester, Minnesota, USA
Aliment Pharmacol Ther 30:775-83. 2009..While knowledge has accumulated regarding health care seeking in several functional gastrointestinal disorders (FGIDs), little is known about health care seeking in those with bloating and distention... - Clinical and pathological implications of IgG antibody responses to Helicobacter pylori and its virulence factors in non-ulcer dyspepsiaH H-X Xia
Department of Medicine, University of Sydney, Nepean Hospital, Penrith, NSW, Australia
Aliment Pharmacol Ther 17:935-43. 2003..Although the 19.5-kDa antigen and VacA were associated with body gastritis, none of the six antigens tested predicted symptom relief after triple therapy... - Irritable bowel syndrome aggregates strongly in families: a family-based case-control studyY A Saito
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Neurogastroenterol Motil 20:790-7. 2008.... - Prevalence and risk factors for abdominal bloating and visible distention: a population-based studyX Jiang
Department of Internal Medicine and Division of Gastroenterology and Hepatology, Mayo Clinic, College of Medicine, Rochester, Minnesota, USA
Gut 57:756-63. 2008..We aimed to evaluate the prevalence and potential risk factors for abdominal bloating and visible distention separately in a representative US population, and their association with other functional gastrointestinal disorders (FGIDs)... - Measurement of abdominal symptoms by validated questionnaire: a 3-month recall timeframe as recommended by Rome III is not superior to a 1-year recall timeframeE Rey
Mayo Clinic College of Medicine, Rochester, MN, USA
Aliment Pharmacol Ther 31:1237-47. 2010..Rome III incorporates changes in the definition of functional gastrointestinal disorder that involve a 3-month recall time for symptoms, rather than 1-year... - A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsiaN J Talley
Department of Medicine, University of Sydney, Sydney, Australia
Aliment Pharmacol Ther 15:525-37. 2001..Patients with adequate relief of upper abdominal pain or discomfort showed improvements in multiple functional dyspepsia symptoms... - Low social class is linked to upper gastrointestinal symptoms in an Australian sample of urban adultsStuart C Howell
School of Public Health, University of Sydney, Sydney, Australia
Scand J Gastroenterol 41:657-66. 2006..001). Diarrhea was not associated with social class whether defined by area disadvantage or education. CONCLUSIONS: Low social class is a risk factor for upper GI complaints... - Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on Functional DyspepsiaN J Talley
Department of Medicine, University of Sydney, Nepean Hospital, New South Wales, Australia
J Gastroenterol Hepatol 13:335-53. 1998..Trials of management strategies are now needed to establish the efficacy and cost-effectiveness of the approaches recommended... - Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general populationH K Jung
Dyspepsia Center and Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Aliment Pharmacol Ther 26:453-61. 2007..Gastro-oesophageal reflux disease (GERD) and irritable bowel syndrome may occur more often than expected by chance, but little community data exists and risk factors are unknown... - Epidemiology of slow and fast colonic transit using a scale of stool form in a communityR S Choung
Dyspepsia Center and Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
Aliment Pharmacol Ther 26:1043-50. 2007..Measurement of gastrointestinal transit is commonly performed in the clinic, but data on transit in the community are lacking... - Functional gastrointestinal disorders among people with sleep disturbances: a population-based studySanthi Swaroop Vege
Division of General Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 79:1501-6. 2004..3; 95% CI, 0.9-1.9). CONCLUSIONS: Both IBS and FD are prevalent in those with self-reported sleep disturbance. Sleep disturbance was independently associated with IBS but not FD in the general population... - Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based studySmita L S Halder
Dyspepsia Center, Enteric Neuroscience Program, Division of Gastroenterology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Gastroenterology 133:799-807. 2007..The natural history of FGID is unknown because of a lack of prospective population-based studies and the indistinct nature of the phenotype. We sought to report the natural history of FGID in a US population... - Opioid bowel dysfunction and narcotic bowel syndrome: a population-based studyRok Seon Choung
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Am J Gastroenterol 104:1199-204. 2009..Despite increasing narcotic use, NBS may be under-recognized. The aim of this study was to assess whether gastrointestinal (GI) symptoms in the community are associated with chronic narcotic use and estimate the likely prevalence of NBS... - Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)N J Talley
Department of Medicine, University of Sydney, Nepean Hospital, Penrith, New South Wales, Australia
Aliment Pharmacol Ther 12:1055-65. 1998..The efficacy of H2-receptor antagonists in functional dyspepsia is equivocal and the therapeutic place of proton pump inhibitors in functional dyspepsia is unknown... - Do distinct dyspepsia subgroups exist in the community? A population-based studyRok Seon Choung
Dyspepsia Center and Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Am J Gastroenterol 102:1983-9. 2007..We aimed to identify these subsets of dyspepsia: "frequent upper abdominal pain (UAP),""early satiety (ES)," and "nausea/vomiting (NV).".. - Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrheaNicholas J Talley
Mayo Foundation, Mayo Medical School, Rochester, Minnesota 55905, USA
Am J Gastroenterol 98:2454-9. 2003..Although there was considerable overlap of upper and lower GI symptoms in patients with IBS-C and IBS-D, the former had more frequent lower abdominal pain and bloating... - Obesity is associated with increased risk of gastrointestinal symptoms: a population-based studySilvia Delgado-Aros
Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.) Program, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
Am J Gastroenterol 99:1801-6. 2004..Clarification of the cause-and-effect relationships and the mechanisms of these associations require further investigation... - Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective studyGanapathy A Prasad
Division of Gastroenterology and Hepatology, GI Epidemiology Outcomes Research Unit, Department of Otolaryngology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Am J Gastroenterol 102:2627-32. 2007..We also aimed to determine the clinical and endoscopic factors predictive of EE in outpatients undergoing endoscopy for dysphagia... - Management of dyspepsiaShehan Abeygunasekera
Department of Medicine, University of Sydney, Nepean Hospital, PO Box 63, Penrith, NSW 2751, Australia
Compr Ther 28:182-9. 2002..Proper management of uninvestigated dyspepsia is a challenging task for any clinician. Efficient and cost-effective management of such patients requires careful history taking and awareness of the available options... - Helicobacter pylori and dyspepsiaN J Talley
Department of Medicine, University of Sydney, Penrith, New South Wales, Australia
Yale J Biol Med 72:145-51. 1999..pylori is etiologically linked to non-ulcer dyspepsia, but data from well designed large randomized controlled trials of eradication therapy, are awaited with great interest... - Diagnostic and therapeutic strategies in the irritable bowel syndromeF Cremonini
Clinical Enteric Neuroscience Translational and Epidemiological Research, CENTER) Program, Mayo Clinic, Rochester, MN, USA
Minerva Med 95:427-41. 2004..Limited evidence suggests that anti-enkephalinase agents, somatostatin analogues, alpha(2)-receptor agonists, opioid antagonists, selective serotonin reuptake inhibitors, probiotics and herbal treatments may be useful in IBS patients... - Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infectionN J Talley
Department of Medicine, The University of Sydney, Nepean Hospital, Penrith 2747, Sydney, Australia
Aliment Pharmacol Ther 15:1603-11. 2001..Functional dyspepsia is a problem that is difficult to treat in clinical practice... - Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trialN J Talley
Department of Medicine, University of Sydney, Nepean Hospital, Penrith NSW, Australia
Gut 49:395-401. 2001..CONCLUSIONS: The motilin agonist ABT-229 was not efficacious in the relief of postprandial symptoms in diabetes mellitus in the presence or absence of delayed gastric emptying... - Is there an association between GNbeta3-C825T genotype and lower functional gastrointestinal disorders?Viola Andresen
Clinical Enteric Neuroscience Translational and Epidemiological Research C E N T E R Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Gastroenterology 130:1985-94. 2006.... - Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation reportBrennan Spiegel
Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA
Gastroenterology 137:1944-53.e1-3. 2009..We pooled data to measure the psychometric properties of IBS end points, including binary responses (eg, "adequate relief") and 50% improvement in symptom severity... - Update on the role of drug therapy in non-ulcer dyspepsiaNicholas J Talley
Department of Medicine, University of Sydney, Nepean Hospital, Penrith, New South Wales, Australia
Rev Gastroenterol Disord 3:25-30. 2003..Therapy for non-ulcer dyspepsia remains challenging and is usually empiric; it will remain so until the mechanisms that induce symptoms of dyspepsia are better understood... - A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut?Nicholas J Talley
Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Rev Gastroenterol Disord 6:72-8. 2006..A new paradigm seems to be needed. All of these disorders may arise after infection or gut inflammation, but the phenotype depends on localized neuromuscular dysfunction in the predisposed human host (the "irritable gut")... - Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based studyHye Kyung Jung
Mayo Clinic, Rochester, Minnesota, USA
Am J Gastroenterol 105:652-61. 2010..We aimed to evaluate this association in the community... - The Rome III Classification of dyspepsia: will it help research?Nicholas J Talley
Mayo Clinic College of Medicine, Jacksonville, Fla, USA
Dig Dis 26:203-9. 2008.... - Obesity and chronic gastrointestinal tract symptoms in young adults: a birth cohort studyNicholas J Talley
Department of Medicine, University of Sydney, Australia
Am J Gastroenterol 99:1807-14. 2004..Hemoglobin A1c levels were not associated with any of the GI symptoms. CONCLUSIONS: In a general population sample of young adults, increasing BMI was associated with diarrhea and abdominal pain with nausea/vomiting... - Oesophageal eosinophilic infiltration in patients with noncardiac chest painS R Achem
Gastroenterology Unit, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Aliment Pharmacol Ther 33:1194-201. 2011..Eosinophilic oesophagitis clinically presents with recurrent episodes of dysphagia and food impaction. Recently, we observed patients with noncardiac chest pain and eosinophilic oesophagitis... - A genetic association study of 5-HTT LPR and GNbeta3 C825T polymorphisms with irritable bowel syndromeY A Saito
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Neurogastroenterol Motil 19:465-70. 2007..05). This study suggests that the 5-HTT LPR polymorphism may be associated with mixed-IBS, but not IBS overall. No association was observed for the GNbeta3 C825T polymorphism with IBS overall or subtypes... - Irritable bowel syndrome: novel views on the epidemiology and potential risk factorsE Rey
Division of Gastroenterology, Mayo Clinic College of Medicine, Rochester, MN, USA
Dig Liver Dis 41:772-80. 2009..The role of diet remains uncertain but under-studied... - Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trialN J Talley
Department of Medicine, University of Sydney, Nepean Hospital, Penrith NSW, Australia Abbott Laboratories, Abbott Park Illinois, USA
Aliment Pharmacol Ther 14:1653-61. 2000..We aimed to test the efficacy of the motilin agonist ABT-229 in functional dyspepsia patients with and without delayed gastric emptying... - Pathophysiology as a basis for understanding symptom complexes and therapeutic targetsM Camilleri
Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Neurogastroenterol Motil 16:135-42. 2004.... - Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in Western Sydney between 1990 and 1998H H Xia
Department of Medicine, The University of Sydney, Nepean Hospital, Penrith, NSW, Australia
Dig Dis Sci 46:2716-23. 2001..The decreased use of NSAIDs and decline of H. pylori infection have likely both contributed to the reduction of peptic ulcer disease, but the increase in reflux esophagitis remains to be fully explained... - Risk factors for non-cardiac chest pain in the communityJ L Wise
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Aliment Pharmacol Ther 22:1023-31. 2005..Non-cardiac chest pain is a common and expensive condition. Risk factors for non-cardiac chest pain are poorly understood and lack description in the USA community... - Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States populationG R Locke
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Aliment Pharmacol Ther 19:1025-31. 2004..The incidence of irritable bowel syndrome is uncertain. We aimed to determine the incidence of clinically diagnosed irritable bowel syndrome in the community... - Review article: Helicobacter pylori and nonulcer dyspepsiaN J Talley
University of Sydney, Nepean Hospital, Penrith, Australia
Aliment Pharmacol Ther 16:58-65. 2002..pylori infection in all patients with NUD. Hence, the management of these patients is challenging, but eradication of H. pylori infection may be beneficial in a small subgroup of cases with NUD that cannot be identified before treatment... - Subtypes of anal incontinence associated with bowel dysfunction: clinical, physiologic, and psychosocial characterizationM D Crowell
Clinical Enteric Neuroscience Translational and Epidemiologic Research CENTER Program, Mayo Foundation and Mayo Clinic, Rochester, Minnesota, USA
Dis Colon Rectum 47:1627-35. 2004..We hypothesized that functional anal incontinence with no structural explanation comprises distinct pathophysiologic subgroups that could be identified on the basis of the predominant presenting bowel pattern... - The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimatesY A Saito
Division of Gastroenterology and Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Neurogastroenterol Motil 15:687-94. 2003..29 (95% CI: 0.19, 0.40), respectively. Thus, although differences were seen with the older criteria, compared with the Rome I criteria, good agreement was seen and community prevalence estimates were similar with the Rome II criteria...
Research Grants
- Antidepressant Therapy for Functional DyspepsiaNicholas Talley; Fiscal Year: 2007..abstract_text> ..
- Antidepressant Therapy for Functional DyspepsiaNicholas Talley; Fiscal Year: 2007..at the top of each printed page and each continuation page. RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page 1 Description, ..